Lanman also collaborated with National Cancer Institute-designated cancer centers to validate two other Guardant products: GuardantOMNI™, a blood test that can predict response to immunotherapy in lung and colon cancer, and LUNAR, a test for early stage cancers and also for the early detection of cancer.